HIKMA Pharmaceuticals PLC
HIK | IL
Overview
Corporate Details
- ISIN(s):
- GB00B0LCW083
- LEI:
- 549300BNS685UXH4JI75
- Country:
- United Kingdom
- Address:
- 1 New Burlington Place, W1S 2HR London
- Website:
- https://www.hikma.com/home/
- Sector:
- Health Care
- Industry:
- Pharmaceuticals
Description
Hikma Pharmaceuticals PLC is a global pharmaceutical company that is dedicated to providing high-quality, affordable medications to patients worldwide. With its headquarters in London, UK, and operations in the Middle East, Africa, Europe, and the United States, Hikma has established itself as a leader in the pharmaceutical industry. The company has a diversified product portfolio that includes branded, generic, and injectable pharmaceuticals. Its focus is on developing and manufacturing innovative solutions for complex diseases, such as oncology, respiratory, and injectables.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-07-09 10:00 |
Report Publication Announcement
Notice of Results
|
English | 12.9 KB | |
| 2025-07-07 10:16 |
Prospectus
Publication of Offering Circular
|
English | 8.0 KB | |
| 2025-06-05 15:05 |
Directors' Dealings
Director/PDMR Shareholding
|
English | 14.4 KB | |
| 2025-06-03 14:02 |
Directors' Dealings
Director/PDMR Shareholding
|
English | 89.1 KB | |
| 2025-05-29 08:00 |
Regulatory News Service
Fitch upgrades Hikma to ‘BBB’
|
English | 11.3 KB | |
| 2025-05-15 13:00 |
Regulatory News Service
Medium-term Group guidance ahead of US site visit
|
English | 12.5 KB | |
| 2025-05-08 11:48 |
Regulatory News Service
S&P upgrades Hikma to ‘BBB’
|
English | 11.3 KB | |
| 2025-05-08 09:21 |
Legal Proceedings Report
Settlement agreement for Xyrem® US lawsuits
|
English | 15.2 KB | |
| 2025-04-30 14:21 |
Directors' Dealings
Director/PDMR Shareholding
|
English | 27.3 KB | |
| 2025-04-24 18:16 |
Declaration of Voting Results & Voting Rights Announcements
Special Business passed at AGM
|
English | 329.0 KB | |
| 2025-04-24 16:55 |
Declaration of Voting Results & Voting Rights Announcements
Result of AGM
|
English | 48.9 KB | |
| 2025-03-19 11:10 |
Report Publication Announcement
Annual Financial Report and Notice of AGM
|
English | 10.4 KB | |
| 2025-03-19 11:10 |
General Meeting Notice
Notice of 2025 Annual General Meeting
|
English | 827.6 KB | |
| 2025-03-19 11:07 |
Annual Report (ESEF)
2024 Annual Report and Accounts
|
English | 9.8 MB | |
| 2025-03-19 11:07 |
Annual Report
2024 Annual Report and Accounts
|
English | 18.6 MB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Nippon Shinyaku Co.,Ltd. | Japan | 4516 | |
|
Noile-Immune Biotech Inc. | Japan | 4893 | |
|
Novartis AG | Switzerland | NOVN | |
|
Nur Ink Innovations Ltd. | Israel | NURI | |
|
Nxera Pharma Co., Ltd. | Japan | 4565 | |
|
ObsEva SA | Switzerland | OBSN | |
|
ODI Pharma AB | Sweden | ODI | |
|
Oncolys BioPharma Inc. | Japan | 4588 | |
|
OncoTherapy Science, Inc. | Japan | 4564 | |
|
OncoZenge AB | Sweden | ONCOZ |